Additionally, there was a reduction in serum IL-6 levels in both head and neck cancer patients (pre-PBMT = 94.10 ± 27.17 pg/mL; post-PBMT = 17.30 ± 2.676 pg/mL; p = 0.0307) and breast cancer patients (pre-PBMT = 99.48 ± 21.74 pg/mL; post-PBMT = 26.93 ± 6.813 pg/mL; p = 0.0190) (Table 3). This evidence concerns the gene IL6 and breast cancer.